Perhaps this is why many medical clinicians are starting to incorporate ivermectin into their COVID-19 treatment protocols. This chart, put out by Johns Hopkins University, is just stunning. Yes, the chart is the result of a correlative study, but it simply cannot be ignored!
Now I see why all the companies that manufacture the COVID-19 gene therapy jabs would prefer that you not know about using ivermectin as a potential prophylaxis and treatment protocol for COVID-19. Why are African countries that use ivermectin to treat onchocerciasis (and other pervasive parasitic infections) showing dramatically lower morbidity and mortality than non-ivermectin countries? What say you FDA? What say you CDC? Perhaps we can learn something from Africa.
If you want more information showing the potential impact of ivermectin on mortality and morbidity in Africa, check out this study by the Tanioka Clinic and Tokyo Medical Center in Japan. Japan seems to be ahead of the pack when it comes to ivermectin. The Tokyo Medical Association endorsed ivermectin back in February 2021.